Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated at Wells Fargo & Company

Investment analysts at Wells Fargo & Company initiated coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note issued to investors on Friday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $17.00 price target on the stock.

ATYR has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Thursday, August 15th. Jefferies Financial Group started coverage on Atyr PHARMA in a research note on Thursday, September 5th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $16.00 target price on shares of Atyr PHARMA in a research note on Wednesday, August 14th.

Atyr PHARMA Stock Up 7.5 %

Shares of ATYR stock opened at $1.87 on Friday. The stock has a market capitalization of $129.05 million, a PE ratio of -2.08 and a beta of 1.21. The company has a current ratio of 7.63, a quick ratio of 7.63 and a debt-to-equity ratio of 0.01. Atyr PHARMA has a fifty-two week low of $1.08 and a fifty-two week high of $2.50. The firm has a fifty day moving average price of $1.85.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, sell-side analysts anticipate that Atyr PHARMA will post -0.91 earnings per share for the current year.

Insider Transactions at Atyr PHARMA

In other Atyr PHARMA news, Director Paul Schimmel bought 52,300 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The stock was purchased at an average cost of $1.93 per share, for a total transaction of $100,939.00. Following the completion of the purchase, the director now owns 413,023 shares of the company’s stock, valued at $797,134.39. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.70% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.